A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors

Grants and Contracts Details

StatusActive
Effective start/end date7/5/217/13/23

Funding

  • Astellas Pharma Global Development Incorporated: $2.00